Glenmark

Glenmark Pharmaceuticals has strengthened its presence in the United States by launching a generic version of Sodium Phosphates Injection, broadening its injectable product portfolio in the world’s largest pharmaceutical market. The launch follows regulatory approval and underscores the company’s strategy of targeting niche, hospital-focused formulations with limited competition. Industry analysts view the move as part of Glenmark’s ongoing pivot toward complex generics and specialty products that offer stronger margins. As pricing pressures persist in the U.S.

Glenmark Pharmaceuticals has entered into a strategic partnership with China-based Hansoh Pharmaceutical to co-develop and commercialize an innovative oncology drug, marking a significant step in its global research-led growth strategy. The collaboration underscores Glenmark’s focus on strengthening its specialty and innovation portfolio while leveraging international partnerships to accelerate drug development. Under the agreement, Glenmark gains rights to develop and market the cancer therapy in select territories, while Hansoh retains manufacturing and development responsibilities.

Pharmaceutical major Glenmark Pharmaceuticals Ltd. has received regulatory approval in China for its RYALTRIS nasal spray, a fixed-dose combination used to treat symptoms of allergic rhinitis. The clearance from Chinese authorities marks a significant milestone in Glenmark’s global respiratory portfolio expansion and strengthens its presence in one of the world’s largest pharmaceutical markets. Developed in-house and marketed across multiple countries, Ryaltris is now approved in over 70 markets worldwide.

In a significant development within the pharmaceutical industry, Indian drugmakers Glenmark Pharmaceuticals and Dr. Reddy's Laboratories have initiated product recalls in the United States due to manufacturing issues, as reported by the U.S. Food and Drug Administration (USFDA). These actions underscore the ongoing challenges faced by global pharmaceutical companies in maintaining stringent quality control standards across diverse manufacturing facilities.

The United States Food and Drug Administration (USFDA) has directed Glenmark Pharmaceuticals, Granules India, and Zydus Lifesciences to recall certain pharmaceutical products from the US market due to quality and safety concerns. The recalls underscore the critical importance of regulatory compliance in global drug exports. While the specific products and batches vary by company, the action highlights challenges faced by Indian pharmaceutical firms operating in stringent overseas markets.

The U.S. Food and Drug Administration (USFDA) has issued recalls for select pharmaceutical products manufactured by Glenmark, Alembic, and Sun Pharma, citing quality and compliance concerns. The recalls affect both prescription and over-the-counter medications distributed in the United States, underscoring ongoing regulatory scrutiny of Indian pharmaceutical exports. Companies have initiated voluntary recall procedures to mitigate risk and ensure consumer safety.

Glenmark Pharmaceuticals has announced the launch of Tevimbra in India, marking its entry into the fast-growing field of immuno-oncology. Approved by the Central Drugs Standard Control Organisation (CDSCO), Tevimbra is indicated for the treatment of advanced non-small cell lung cancer (NSCLC) and oesophageal squamous cell carcinoma (ESCC). Originally developed by global biotech leader BeiGene (now BeOne Medicines), Tevimbra has already been approved in the U.S., EU, China, and Australia.

Glenmark Pharmaceuticals announced that its Monroe, North Carolina manufacturing plant has received a Form 483 from the United States Food and Drug Administration (USFDA) following a routine inspection. Conducted between June 9 and June 17, 2025, the inspection resulted in five procedural observations, with no findings related to data integrity. Glenmark emphasized its commitment to addressing the issues in a timely manner, in cooperation with the regulatory agency. While the regulatory scrutiny garnered attention, the company’s stock remained stable, edging up 0.22% to close at Rs.

Glenmark Pharmaceuticals announced plans on Monday to introduce zanubrutinib, a cutting-edge cancer treatment, to the Indian market. The move follows the recent approval of the drug by the Drugs Controller General of India (DCGI). Zanubrutinib, which will be marketed under the brand name Brukinsa, represents a significant milestone for Glenmark’s oncology portfolio and expands therapeutic options for patients suffering from five distinct types of B-cell malignancies.